Clearside biomedical's positive odyssey wet amd data and suprachoroidal injection platform highlighted in presentations at multiple events during aao 2024 annual meeting

- cls-ax phase 3 ready based on positive phase 2b topline data in wet amd - - differentiated profile for cls-ax targeting flexible dosing similar to a biologic with the potential extended duration of a tyrosine kinase inhibitor (tki) - - versatility of scs microinjector ® featured in multiple presentations - alpharetta, ga., oct. 22, 2024 (globe newswire) -- clearside biomedical, inc. (nasdaq: clsd), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (scs®), announced today that multiple presentations were delivered at the 2024 annual meeting of the american academy of ophthalmology (aao) and preceding events that highlighted encouraging safety and efficacy data from clinical trials of therapies utilizing clearside's scs microinjector® to deliver drugs into the suprachoroidal space to treat a variety of retinal diseases.
AMD Ratings Summary
AMD Quant Ranking